Stock Market Live July 1, 2026: S&P 500 (SPY) Lower as Investors Wait on the Fed and Fresh Economic Data
Q3 25 EPS
$-0.36
BEAT +5.69%
Est. $-0.38
Q3 25 Revenue
$5.2M
MISS 73.27%
Est. $19.4M
vs S&P Since Q3 25
-36.8%
TRAILING MARKET
RXRX -26.5% vs S&P +10.2%
Market Reaction
Did RXRX Beat Earnings? Q3 2025 Results
Recursion Pharmaceuticals delivered a mixed but strategically eventful Q3 2025, posting a narrower-than-expected loss while falling well short of revenue forecasts. The AI-driven biotech reported a loss of $0.36 per share, beating the consensus estim… Read more Recursion Pharmaceuticals delivered a mixed but strategically eventful Q3 2025, posting a narrower-than-expected loss while falling well short of revenue forecasts. The AI-driven biotech reported a loss of $0.36 per share, beating the consensus estimate of $0.38 by 5.69%, yet revenue collapsed 80.2% year-over-year to just $5.17 million, missing the $19.36 million consensus by 73.27%. The steep revenue decline was largely a timing artifact: a $30 million Roche/Genentech milestone had inflated the year-ago quarter, while the company's next $30 million milestone for a microglia whole-genome phenomap, achieved in October 2025, will be partially recognized in Q4. Net losses widened to $162.25 million, reflecting higher R&D costs tied to the Exscientia combination and REC-102 rights acquisition. Against that backdrop, the company crossed $500 million in cumulative partner milestones and held roughly $785 million in cash, supporting runway through year-end 2027, with management projecting more than $100 million in partnership milestone payments by end of 2026.
Key Takeaways
- • Achievement of $30 million Roche/Genentech milestone for second neuroscience phenomap (microglia map)
- • Cumulative partnership milestones and upfront payments exceeding $500 million
- • $387.5 million in net ATM proceeds raised during Q3 and Q4 2025
- • Exscientia business combination completed November 2024 expanding platform capabilities
RXRX YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
“Recursion continues to deliver on our internal pipeline, our strategic partnerships and the continued building and refinement of the Recursion OS. On the partnership front, we are proud to announce that with the option of our second neuro map in the Roche and Genentech collaboration, we've achieved over $500 million in upfront and milestone payments from our partners to date as we continue to deliver novel insights and advance programs for some of the toughest disease areas.”
— Chris Gibson, Q3 2025 Earnings Press Release
RXRX Earnings Trends
RXRX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
RXRX EPS Trend
Earnings per share: estimate vs actual
RXRX Revenue Trend
Quarterly revenue: estimate vs actual
RXRX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.26 | $-0.22 | +14.43% | $6.5M | -58.98% |
| Q4 25 BEAT FY | $-0.32 | $-0.21 | +33.35% | $35.5M | +44.71% |
| FY Full Year | $-1.60 | $-1.44 | +10.08% | $74.7M | +21.21% |
| Q3 25 BEAT | $-0.38 | $-0.36 | +5.69% | $5.2M | -73.27% |
| Q2 25 MISS | $-0.35 | $-0.41 | -16.05% | $19.2M | +24.96% |
| Q1 25 BEAT | $-0.52 | $-0.50 | +3.10% | $14.7M | -18.46% |